3 completed, 1 suspended, 1 terminated. 1 Not applicable, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Recurrent Vulvar Carcinoma: new trials by email Literature Review of Recurrent Vulvar Carcinoma trials Research Report on Recurrent Vulvar Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paclitaxel Therapeutic Drug Monitoring in Cancer Patients Blood draws, QLQ-CIPN20 Survey, PR-CTCAE Survey - Solid Tumor, Adult, Metastatic Nonsmall Cell Lung Cancer | Suspended | Wake Forest University Health Sciences | 55 | 2019-11-11 | 2026-08-13 | |
| DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab - Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive | Phase 2 | Terminated | M.D. Anderson Cancer Center | 41 | 2018-11-14 | 2024-07-09 |
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers Durvalumab, Laboratory Biomarker Analysis, Stereotactic Radiosurgery - Advanced Cervical Adenocarcinoma, Advanced Vaginal Carcinoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 20 | 2018-07-18 | 2023-09-13 |
| Palliative Care in Improving Quality of Life in Patients With High Risk Primary or Recurrent Gynecologic Malignancies Palliative Therapy, Palliative Therapy + idiographic - Cervical Carcinoma, Ovarian Carcinoma | Not applicable | Completed | Albert Einstein College of Medicine | 95 | 2015-04-01 | 2019-09-17 |
| Collecting Tumor Samples From Patients With Gynecological Tumors Laboratory Biomarker Analysis - Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor | Completed | Gynecologic Oncology Group | 275 | 1992-06-01 | 2016-10-28 |
Uterine Cervical Neoplasms (5) · Vulvar Neoplasms (5) · Ovarian Neoplasms (3) · Vaginal Neoplasms (3) · Anal Canal Carcinoma (1) · Anus Neoplasms (1) · Breast Neoplasms (1) · Brenner Tumor (1) · Carcinoma, Non-Small-Cell Lung (1) · Fallopian Tube Neoplasms (1) · Gestational Trophoblastic Disease (1) · Lung Neoplasms (1) · Melanoma (1) · Mesothelioma, Malignant (1) · Neoplasm Metastasis (1)
Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Neoplasms by Site (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Uterine Cervical Diseases (5) · Uterine Diseases (5) · Vulvar Diseases (5) · Neoplasms (4) · Uterine Neoplasms (4) · Adnexal Diseases (3) · Endocrine Gland Neoplasms (3)
Disulfides (2) · Immunoglobulin G (2) · durvalumab (2) · Blood Specimen Collection (1) · MEDI0457 (1) · Palliative Care (1) · Radiosurgery (1) · VGX-3100 (1) · rocakinogene sifuplasmid (1) · tremelimumab (1)
M.D. Anderson Cancer Center (2) · Albert Einstein College of Medicine (1) · Gynecologic Oncology Group (1) · Wake Forest University Health Sciences (1)
United States (5)
Lilie L Lin (1) · Michael Cibull (1) · Michael M Frumovitz (1) · Nicole Nevadunsky (1) · Roy Strowd, MD (1)
P30CA012197 (1), P30CA013330 (1), U10CA180868 (1)